{"abstract":"This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive license to practice the inventions embodied in U.S. Patent Application 61/172,099 entitled \"Anti-human ROR1 Antibodies\" [HHS Ref. E-097-2009/0-US-01], U.S. Patent Application 60/703,798 entitled \"Mutated Pseudomonas Exotoxins with Reduced Antigenicity\" [HHS Ref. E-262-2005/0-US-01], U.S. Patent Application 60/969,929 entitled \"Deletions in Domain II of Pseudomonas Exotoxin A that Remove Immunogenic Epitopes with Affecting Cytotoxic Activity\" [HHS Ref. E- 292-2007/0-US-01], U.S. Patent Application 61/241,620 entitled \"Improved Pseudomonas Exotoxin A with Reduced Immunogenicity\" [HHS Ref. E-269-2009/0-US-01], U.S. Patent Application 61/483,531 entitled \"Recombinant Immunotoxin Targeting Mesothelin\" [HHS Ref. E-117-2011/ 0-US-01], U.S. Patent Application 61/495,085 entitled \"Pseudomonas Exotoxin A with Less Immunogenic T-Cell/or B-Cell Epitopes\" [HHS Ref. E-174-2011/0-US-01], U.S. Patent Application 61/535,668 entitled \"Pseudomonas Exotoxin A with Less Immunogenic B-Cell Epitopes\" [HHS Ref. E-263-2011/0-US-01], and all related continuing and foreign patents/patent applications for the technology family, to SPEED BioSystems, LLC. The patent rights in these inventions have been assigned to the Government of the United States of America. The prospective exclusive evaluation option license territory may be worldwide and the field of use may be limited to pre-clinical evaluation of lead therapeutic candidates for the development and use of anti-tyrosine kinase-like orphan receptor 1 (ROR1) targeted immunotoxins for the treatment of human ROR1 expressing cancers, wherein the immunotoxin comprises an anti-ROR1 antibody designated as 2A2 and Pseudomonas exotoxin A (PE). Upon expiration or termination of the exclusive evaluation option license, SPEED will have the right to execute an exclusive patent commercialization license which will supersede and replace the exclusive evaluation option license with no broader territory than granted in the exclusive evaluation option license and the field of use will be commensurate with the commercial development plan at the time of conversion.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2013/04/09/2013-08148.html","cfr_references":[],"citation":"78 FR 21131","comment_url":null,"comments_close_on":"2013-04-24","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before April 24, 2013 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2013-08148","effective_on":null,"end_page":21132,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2013/04/09/2013-08148.xml","html_url":"https://www.federalregister.gov/documents/2013/04/09/2013-08148/prospective-grant-of-an-exclusive-evaluation-option-license-pre-clinical-evaluation-of-anti-tyrosine","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2013-08148?publication_date=2013-04-09","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2013-04-09/2013-08148/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":113,"last_updated":"2026-07-28 06:15:03 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2013-04-09/pdf/2013-08148.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2013-08148.pdf?1365425726","publication_date":"2013-04-09","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2013/04/09/2013-08148.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"supporting_documents":[],"comments_url":"https://www.regulations.gov/docketBrowser?rpp=50&so=DESC&sb=postedDate&po=0&dct=PS&D=NIH_FRDOC_0001","supporting_documents_count":0,"docket_id":"NIH_FRDOC_0001","regulation_id_number":null,"title":"Recently Posted NIH Rules and Notices.","checked_regulationsdotgov_at":"2013-04-29T06:00:14Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":21131,"subtype":null,"title":"Prospective Grant of An Exclusive Evaluation Option License: Pre-clinical Evaluation of Anti-tyrosine Kinase-like Orphan Receptor 1 Immunotoxins for the Treatment of Human Cancers","toc_doc":"Pre-clinical Evaluation of Anti-tyrosine kinase-like orphan receptor 1 Immunotoxins for the Treatment of Human Cancers","toc_subject":"Exclusive Evaluation Option Licenses:","topics":[],"type":"Notice","volume":78}